Table 2 The clinical characteristics of AML patients from TCGA. CR, complete remission; MLL, mixed lineage leukemia
|  | TCGAPO (N = 74) | TCGAPT (N = 73) |
|---|---|---|
Age at Diagnosis (year) | ||
 median (range) | 10.58 (0.40–22.55) | 9.04 (0.38–19.12) |
Gender | ||
 female (n%) | 34 (45.95%) | 40 (54.79%) |
Race | ||
 white (n%) | 59 (79.73%) | 55 (75.34%) |
First event | ||
 relapse (n%) | 51 (68.92%) | 54 (73.97%) |
CR status | ||
 CR (n%) | 69 (93.24%) | 61 (83.56%) |
Primary Cytogenetic | ||
 MLL (n%) | 10 (13.51%) | 18 (24.66%) |
 Normal (n%) | 18 (24.32%) | 11 (15.07%) |
 Other (n%) | 14 (18.92%) | 20 (27.40%) |
 t(8;21) | 7 (9.46%) | 11 (15.07%) |
 inv.(16) | 16 (21.62%) | 12 (16.44%) |
Cytogenetic Site of Relapse/Induction Failure | ||
 Yes (n%) | 4 (5.41%) | 13 (17.81%) |
 No (n%) | 48 (64.86%) | 43 (58.90%) |
 Not done (n%) | 22 (29.73%) | 17 (23.29%) |
FAB Category | ||
 M0,M1,M2,M3,M4,M5,M6,M7,NOS | 2 (2.70%),7 (9.46%),19 (25.68%),0 (0.00%),22 (29.73%),15 (20.27%),1 (1.35%),2 (2.70%),5 (6.76%) | 2 (2.74%),8 (10.96%),15 (20.55%),0 (0.00%),20 (27.40%),12 (16.44%),1 (1.37%),5 (6.85%),3 (4.11%) |
FLT3/ITD | ||
 Positive (n%) | 8 (10.81%) | 5 (6.85%) |
 Negative (n%) | 66 (89.19%) | 68 (93.15%) |
WBC at Diagnosis | ||
 median (range) | 53.5 (2.1–302) | 34.9 (1.3–519) |
NPM mutation | ||
 Yes (n%) | 4 (5.41%) | 2 (2.74%) |
 No (n%) | 66 (89.19%) | 70 (95.89%) |
CEBPA mutation | ||
 Yes (n%) | 4 (5.41%) | 5 (6.85%) |
 No (n%) | 69 (93.24%) | 67 (91.78%) |
WT1 mutation | ||
 Yes (n%) | 4 (5.41%) | 6 (8.22%) |
 No (n%) | 67 (90.54%) | 66 (90.41%) |
Protocol | ||
 CCG-2961(n%), AAML03P1(n%), AAML0531(n%) | 18 (24.3%),38 (51.4%),18 (24.3%) | 0 (0%),0 (0%),73 (100%) |